Managing blood pressure and heart risks during BTKi treatment
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at how well blood pressure is managed and whether heart problems can be prevented in people with certain blood cancers who are taking a type of targeted therapy called a BTKi. It aims to help you stay healthier during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of blood cancer: CLL, mantle cell lymphoma, Waldenstrom macroglobulinemia, or marginal zone lymphoma.
- You are about to start treatment with a medication called a Bruton tyrosine kinase inhibitor (BTKi), or switch to a new one after a 5-day break.
- You are willing to return to the Mayo Clinic for regular check-ups during the study.
- Your cancer has not spread to your brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a connected blood pressure monitor to track blood pressure changes in patients with blood cancers who are starting a type of targeted drug called a BTK inhibitor. Researchers want to see if home monitoring helps catch and manage blood pressure changes early.
This study looks at whether starting certain blood cancer treatments (BTK inhibitors or others like venetoclax) affects heart rhythm. It focuses on people with specific blood cancers who are starting a new treatment, to check for new or worsening atrial fibrillation.
This study follows patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)—blood cancers—who have been taking a type of targeted drug called a BTK inhibitor for at least 2 years. Researchers want to understand what happens to these patients' cancer and health after they stop taking this medication.
This study watches for high blood pressure and irregular heartbeats in people with CLL who are starting a type of targeted therapy called a BTK inhibitor (acalabrutinib or zanubrutinib). Researchers will use a smartwatch and blood pressure cuff to monitor your heart health at home.
This observational study tracks how your heart rhythm (heartbeat pattern) changes while you take a BTK inhibitor or venetoclax. It may help doctors better understand heart rhythm risks in people receiving these cancer-related medicines.
This Phase 1/2 trial studies the safest dose and then effectiveness of BGB-16673 in people with specific B-cell malignancies. It may help by targeting cancer cells in these blood cancers, especially after other treatments like BTK inhibitors.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.